# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001648257-26-000043
**Filing Date:** 2026-6
**Character Count:** 9618
**Document Hash:** 398750b89f168f41a5ae44b70afaa0b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001648257-26-000043.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001648257-26-000043

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260629

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 261131169

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2026**

**Commission File Number: 001-37710**

------

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

------

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**

(Address of principal executive offices)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

------

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

<u>EXHIBIT INDEX</u>

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| Exhibit 99.1 | Announcement relating to blocklisting six monthly return |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| HUTCHMED (CHINA) LIMITED | HUTCHMED (CHINA) LIMITED |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |

---

Date: June 29, 2026

------

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](hcm-20260629xex99d1001.gif)

**Blocklisting Six Monthly Return**

**Hong Kong, Shanghai, & Florham Park, NJ — Monday, June 29, 2026:** HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

---

| | | |
|:---|:---|:---|
| 1. | Name of applicant:<br>| HUTCHMED (China) Limited  |
| 2. | Name of scheme: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>(a)<br>Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme")<br>(b)<br>Share Option Scheme adopted by HUTCHMED in 2026 ("2026 HUTCHMED Share Option Scheme") |
|  | Name of scheme: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>(a)<br>Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme")<br>(b)<br>Share Option Scheme adopted by HUTCHMED in 2026 ("2026 HUTCHMED Share Option Scheme") |
| 3. | Period of return:<br>| From December 29, 2025 to June 28, 2026 |
| 4. | Balance under scheme from previous return: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US$0.1 each<br>(b)<br>2026 HUTCHMED Share Option Scheme: Nil |
| 4. | Balance under scheme from previous return: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US$0.1 each<br>(b)<br>2026 HUTCHMED Share Option Scheme: Nil |
| 5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:  | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: Nil<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each |
|  | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:  | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: Nil<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each |
| 6. | Number of securities issued/allotted under scheme during period: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>(a)<br>2015 HUTCHMED Share Option Scheme: 7,500<br>(b)<br>2026 HUTCHMED Share Option Scheme: Nil |
|  | Number of securities issued/allotted under scheme during period: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>(a)<br>2015 HUTCHMED Share Option Scheme: 7,500<br>(b)<br>2026 HUTCHMED Share Option Scheme: Nil |
| 7. | Balance under scheme not yet issued/allotted at end of the period: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 45,768,368 ordinary shares of US$0.1 each<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each |
|  | Balance under scheme not yet issued/allotted at end of the period: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 45,768,368 ordinary shares of US$0.1 each<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each |
| 8. | Number and class of securities originally listed and the date of admission: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission scheme following the Company's share subdivision which took effect on May 30, 2019)<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each admitted on June 11, 2026 following its adoption at the annual general meeting held on May 12, 2026 |
|  | Number and class of securities originally listed and the date of admission: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission scheme following the Company's share subdivision which took effect on May 30, 2019)<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each admitted on June 11, 2026 following its adoption at the annual general meeting held on May 12, 2026 |
|  | Number and class of securities originally listed and the date of admission: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission scheme following the Company's share subdivision which took effect on May 30, 2019)<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each admitted on June 11, 2026 following its adoption at the annual general meeting held on May 12, 2026 |
|  | Number and class of securities originally listed and the date of admission: | &nbsp;&nbsp;&nbsp;&nbsp;(a)<br>2015 HUTCHMED Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission scheme following the Company's share subdivision which took effect on May 30, 2019)<br>(b)<br>2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each admitted on June 11, 2026 following its adoption at the annual general meeting held on May 12, 2026 |
|  | Number and class of securities originally listed and the date of admission: |  |
| 9. | Total number of securities in issue at the end of the period:<br>| 872,335,120 ordinary shares of US$0.1 each |
| Name of contact: | Name of contact: | Weiguo Su / Johnny Cheng |

---

------

Address of contact: Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong <br> Telephone number of contact: +852 2121 8200

**About HUTCHMED**

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** | +852 2121 8200 / <u>ir@hutch-med.com</u> |
| **Media Enquiries** |  |
| FTI Consulting – | +44 20 3727 1030 / <u>HUTCHMED@fticonsulting.com</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Ben Atwell / Tim Stamper | &nbsp;&nbsp;&nbsp;&nbsp;+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / <u>HUTCHMED@brunswickgroup.com</u> |
| **Panmure Liberum** | *Nominated Advisor and Joint Broker* |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| **Cavendish** | *Joint Broker* |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| **Deutsche Numis** | *Joint Broker* |
| Duncan Monteith / Ramin Naji | +44 20 7545 8000 |

---

------